Mitchell Brigell
Technik-/Wissenschafts-/F&E-Leiter bei OCUPHIRE PHARMA, INC.
Profil
Mitchell Brigell is currently the Vice President-Clinical Development at Aerpio Therapeutics, Inc. and the Head-Clinical Development & Strategy at Ocuphire Pharma, Inc. Previously, he held the position of Executive Director-Translational Medicine at Novartis Institutes of Biomedical Research from 2007 to 2013 and Vice President-Clinical Development at Aerpio Pharmaceuticals, Inc. from 2013 to 2019.
He also served as the Vice President-Americas Region at ISCEV.
Dr. Brigell holds a doctorate degree from Kansas State University.
Aktive Positionen von Mitchell Brigell
Unternehmen | Position | Beginn |
---|---|---|
OCUPHIRE PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Mitchell Brigell
Unternehmen | Position | Ende |
---|---|---|
AERPIO PHARMACEUTICALS | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2019 |
Novartis Institutes of Biomedical Research
Novartis Institutes of Biomedical Research BiotechnologyHealth Technology Novartis Institutes of Biomedical Research operates a pharmaceutical research organization. The private company is based in Emeryville. | Corporate Officer/Principal | 01.08.2013 |
ISCEV | Corporate Officer/Principal | - |
Ausbildung von Mitchell Brigell
Kansas State University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
OCUPHIRE PHARMA, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Health Technology |
Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |
Novartis Institutes of Biomedical Research
Novartis Institutes of Biomedical Research BiotechnologyHealth Technology Novartis Institutes of Biomedical Research operates a pharmaceutical research organization. The private company is based in Emeryville. | Health Technology |
ISCEV |